(ELVN)

NMS – Real vaqt narxi. Valyuta: USD

38.83

-0.46 (-1.17%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

38.25

-0.58 (-1.49%)

Bozordan keyin: Mar 27, 2026, 7:33 PM EDT

28.03.2026

Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million

Helen Louise Collins exercised and sold 40,000 Common Stock shares over March 9–10, 2026, generating proceeds of ~$1.20 million at a weighted average price of $30.07 per share. The transaction reduced her direct Common Stock holdings by 61.54%, from 65,000 to 25,000 shares, while indirect holdings remained at zero.

25.02.2026

Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

BOULDER, Colo., Feb. 25, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:30 a.m.

01.02.2026

Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k

Enliven Therapeutics' Chief Scientific Officer sold 20,000 indirect shares for a total of approximately $535,100 on Jan. 20, 2026, at a weighted average price of around $26.75 per share. The sale represented 2.61% of the executive's holdings, reducing his trust's position from 765,188 to 745,188 shares as reported in the SEC Form 4.

08.01.2026

Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars

Enliven Therapeutics Inc. (NASDAQ: ELVN) stock is trading higher on Thursday, with a session volume of 6.61 million compared to the average volume of 631.52 thousand as per data from Benzinga Pro.

08.01.2026

Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones

Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts ELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels evaluated, consistent with previously reported data Data further reinforce ELVN-001's positioning as the potentially best-in-class active-site TKI in CML Multiple key data, regulatory and operational catalysts expected in 2026 BOULDER, Colo., Jan. 8, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced positive initial data from the ongoing Phase 1b ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) that is relapsed, refractory or intolerant to available tyrosine kinase inhibitors (TKIs) (NCT05304377).

07.01.2026

Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

Scott Garland, a seasoned biopharma executive with a strong track record of leading successful companies and drug launches, joins Enliven's Board of Directors Building on positive data reported in 2025, Enliven continues to prepare for Phase 3 trial initiation in 2026 and the commercialization of ELVN-001 BOULDER, Colo., Jan. 7, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the appointment of Scott Garland to its Board of Directors and the planned resignation of Andrew Phillips, Ph.D.

11.12.2025

Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

BOULDER, Colo., Dec. 11, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. ("Enliven"), (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that on December 11, 2025, Enliven granted an inducement stock option to purchase 875,000 shares of Enliven's common stock to Richard Fair, Enliven's President and Chief Executive Officer and member of the board of directors, in connection with the commencement of Richard Fair's employment.

Videolar

No Data

There is no data to display

Press-relizlar

08.01.2026

Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones

07.01.2026

Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

11.12.2025

Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

11.12.2025

Enliven Therapeutics Announces New CEO to Drive Next Phase of Development

Rick Fair, a seasoned executive with deep experience developing and commercializing hematology products, joins Enliven as Chief Executive Officer Co-Founder Sam Kintz will assume a new position as Head of Pipeline BOULDER, Colo. , Dec. 11, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the appointment of Rick Fair as Chief Executive Officer and member of the Board of Directors of Enliven, effective December 11, 2025.

(ELVN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

(ELVN)

Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million

Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k

Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars

Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones

Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

Videolar

No Data

Press-relizlar

Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones

Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

Enliven Therapeutics Announces New CEO to Drive Next Phase of Development

Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million

Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k

Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars

Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones

Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

Videolar

No Data

Press-relizlar

Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones

Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

Enliven Therapeutics Announces New CEO to Drive Next Phase of Development